The launch of dupilumab biosimilars is anticipated in 2026 [1]. This timeline is based on the expected expiry of key patents protecting the original drug, Dupixent, which is manufactured by Sanofi and Regeneron [1][2].
When do dupilumab patents expire?
The primary patents for dupilumab are expected to expire in 2026 [1]. DrugPatentWatch.com tracks these patent expiries, which are crucial for determining when biosimilar competition can enter the market [1].
Who makes dupilumab?
Dupilumab, marketed as Dupixent, is developed and manufactured through a collaboration between Sanofi and Regeneron [2].
How do biosimilars compare to the original drug?
Biosimilars are highly similar to the original biologic drug, known as the reference product. They are approved by regulatory agencies and demonstrate no clinically meaningful differences in terms of safety, purity, and potency. This means they are expected to have the same clinical effect as the reference product [3].
What does a dupilumab biosimilar launch mean for patients?
The introduction of biosimilars can lead to increased competition, which often results in lower drug prices. This could improve patient access to dupilumab treatments for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [2][3].
Are there any challenges to a 2026 dupilumab biosimilar launch?
Patent litigation is common in the pharmaceutical industry. Companies developing biosimilars may face legal challenges from the originator companies aiming to extend market exclusivity. The exact timing of a biosimilar launch can depend on the outcomes of these legal proceedings and any potential settlement agreements [1].
What other dupilumab-related launches are expected?
While the 2026 timeframe primarily refers to biosimilars, other developments could also influence the market. However, the most significant anticipated event impacting market entry is the expiry of the core patents [1].
Sources:
1. DrugPatentWatch.com
2. Sanofi and Regeneron Pharmaceuticals, Inc.
3. U.S. Food and Drug Administration (FDA)